Pipeline
The BBB Breakthrough
Antibody Therapeutics
TRANSMAB
TRANSMAB
TRANSMAB
®
®
Pipeline
Pipeline
Pipeline
Candidate
Candidate
Target
Indication
Stage
INR301
PD-L1
Alzheimer's
P
P1
P2
P3
L
Description
INR301 is a first-in-class, BBB-penetrating anti–PD-L1 antibody that introduces a novel immunological approach to Alzheimer’s disease—restoring brain immune homeostasis by modulating astrocyte–microglia–neuron communication.
INR301
PD-L1
Alzheimer's
P
P1
P2
P3
L
Description
INR301 is a first-in-class, BBB-penetrating anti–PD-L1 antibody that introduces a novel immunological approach to Alzheimer’s disease—restoring brain immune homeostasis by modulating astrocyte–microglia–neuron communication.
INR301
PD-L1
Alzheimer's
P
P1
P2
P3
L
Stage
Description
INR301 is a first-in-class, BBB-penetrating anti–PD-L1 antibody that introduces a novel immunological approach to Alzheimer’s disease—restoring brain immune homeostasis by modulating astrocyte–microglia–neuron communication.
INR302
Undisclosed
Alzheimer's
D
P
P1
P2
P3
INR302
Undisclosed
Alzheimer's
D
P
P1
P2
P3
INR302
Undisclosed
Alzheimer's
D
P
P1
P2
P3
Stage
INR303
Undisclosed
Neurodegeneration
D
P
P1
P2
P3
INR303
Undisclosed
Neurodegeneration
D
P
P1
P2
P3
INR303
Undisclosed
Neurodegeneration
D
P
P1
P2
P3
Stage